Sort
30,917 grants matching “tumor microenvironment”
Eco-evolutionary drivers of clonal dynamics during UV-induced skin carcinogenesis (PQ3)
$640,021Kenneth Y Tsai · H. Lee Moffitt Cancer Ctr & Res Inst · R01 · FY2021 · CA
Elucidating the molecular mechanisms of metastasis organ tropism
$639,882Charles M Perou · Univ Of North Carolina Chapel Hill · U01 · FY2025 · CA
An integrated microtechnology platform for spatially resolved mass spectrometry-based proteomics
$639,750Sindy Kam-Yan Tang · Stanford University · R01 · FY2023 · CA
Immunotherapy via engineered therapeutic programs in tumors using RNA
$639,680Ron Weiss · Massachusetts Institute Of Technology · U01 · FY2025 · CA
Radiomic spatial maps for identifying viable tumor extent on multi-parametric MRI for Glioblastoma
$639,642Pallavi Tiwari · University Of Wisconsin-Madison · R01 · FY2024 · CA
Mechanisms of tumorigenesis in Brg1 mutant lung cancer
$639,553Carla F. Kim · Boston Children'S Hospital · R01 · FY2019 · CA
The Impact of FUS-Mediated Brain Cancer Therapy on BBB Transport, Cytokines, and Immunocyte Trafficking
$639,521Kim Butts Pauly · Stanford University · R01 · FY2018 · CA
Novel targeted therapy for treating Ovarian Cancer
$639,397Ratna K Vadlamudi · University Of Texas Hlth Science Center · R01 · FY2024 · CA
P-selectin-Mediated Targeting of PI3K Nanomedicines to the Tumor Microenvironment
$639,270Daniel Alan Heller · Sloan-Kettering Inst Can Research · R01 · FY2020 · CA
P-selectin-Mediated Targeting of PI3K Nanomedicines to the Tumor Microenvironment
$639,270Daniel Alan Heller · Sloan-Kettering Inst Can Research · R01 · FY2021 · CA
Serial immunotherapy combination to modulate the tumor environment in patients with metastatic gastroesophageal cancer
$639,268Harry H Yoon · Mayo Clinic Rochester · R01 · FY2022 · CA
Mechanisms of BET bromodomain metabolic reprogramming in triple negative breast cancer
$639,256Gerald V Denis · Boston University Medical Campus · R01 · FY2020 · CA
ECM geometrical and mechanical properties modulate RTK signaling
$639,231Jay T. Groves · University Of California Berkeley · U01 · FY2018 · CA
ECM geometrical and mechanical properties modulate RTK signaling
$639,231Jay T. Groves · University Of California Berkeley · U01 · FY2016 · CA
(8) Genomic determinants of the T-cell regulome in immune checkpoint blockade
$639,149Tomas Kirchhoff · New York University School Of Medicine · R01 · FY2020 · CA
Co-Clinical Research Resource for Imaging Tumor Associated Macrophages
$639,130Heike Elizabeth Daldrup-Link · Stanford University · U24 · FY2023 · CA
A phase I/II study of combined therapy with Th17-inducing dendritic cells and pembrolizumab in patients with recurrent epithelial ovarian cancer
$639,109Keith L Knutson · Mayo Clinic Jacksonville · R01 · FY2025 · CA
Targeting Intrinsic and Extrinsic Barriers to Treat Metastatic Pancreatic Cancer
$639,098Scott Andrew Gerber · University Of Rochester · R01 · FY2025 · CA
A model for predicting response to PD-1 inhibitors in NSCLC
$639,083Edward B Garon · University Of California Los Angeles · R01 · FY2017 · CA
Project 3: Analysis of intrinsic and extrinsic factors that promote prostate neuroendocrine differentiation
$639,074Michael M. Shen · Columbia University Health Sciences · P01 · FY2022 · CA
Project 2: Investigating cell intrinsic and extrinsic drivers of prostate cancer bone metastasis
$639,074Cory Abate-Shen · Columbia University Health Sciences · P01 · FY2022 · CA
A physical sciences approach to investigate the role of exosomes in metastatic progression
$639,040Ravi Radhakrishnan · University Of Pennsylvania · U01 · FY2024 · CA
NT-I7, a novel long-acting interleukin-7, in combination with anti-PD-1 checkpoint blockade for the treatment of glioablastoma
$639,004Jian Campian · Mayo Clinic Rochester · R01 · FY2025 · CA
Leveraging CD26high Meso-CAR T cells in patients with advanced pancreatic cancer
$638,929Gregory B. Lesinski · Emory University · R01 · FY2025 · CA
A novel preclinical model of spontaneous metastasis
$638,924Glenn T. Merlino · Division Of Basic Sciences - Nci · ZIA · FY2015 · CA